Surface Oncology (DB:QSOA) - Cotización, noticias y análisis

Resumen de acción QSOA

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. Saber más

Análisis fundamental de QSOA
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	0/6
Rendimiento pasado	0/6
Salud financiera	4/6
Dividendos	0/6

Análisis de riesgos

Alta volatilidad del precio de la acción en los últimos 3 meses

Tiene menos de 1 año de cash runway

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Los accionistas han sido diluidos en el último año

+ 2 riesgos adicionales

Competidores de Surface Oncology, Inc.

4SC

DB:VSC

€51.9m

Medigene

XTRA:MDG1

€20.6m

Heidelberg Pharma

XTRA:HPHA

€106.7m

2invest

XTRA:2INV

€63.2m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Surface Oncology
Precios históricos de las acciones
Precio actual de la acción	US$0.99
Máximo en las últimas 52 semanas	US$1.41
Mínimo de 52 semanas	US$0.52
Beta	1.75
1Cambio en 1 mes	16.19%
Variación en 3 meses	36.16%
Cambio de 1 año	-27.10%
3Variación en 3 años	-82.41%
Variación en 5 años	-88.77%
Variación desde la OPV	-90.74%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	QSOA	DE Biotechs	Mercado DE
7D	-0.7%	0.8%	0.8%
1Y	-27.1%	-18.3%	8.6%

Rentabilidad vs. Industria: Los resultados de QSOA fueron inferiores a los de la industria German Biotechs, que obtuvo un rendimiento del -18.3% el año pasado.

Rentabilidad vs. Mercado: QSOA obtuvo unos resultados inferiores a los del mercado German, que fueron del 8.6% el año pasado.

Volatilidad de los precios

Is QSOA's price volatile compared to industry and market?
QSOA volatility
QSOA Average Weekly Movement	12.0%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: El precio de las acciones de QSOA ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de QSOA(12%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de German.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2014	35	Rob Ross	www.surfaceoncology.com

Resumen de fundamentos de Surface Oncology, Inc.

¿Cómo se comparan los beneficios e ingresos de Surface Oncology con su capitalización de mercado?
Estadísticas fundamentales de QSOA
Capitalización bursátil	€60.83m
Beneficios(TTM)	-€86.46m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-0.7x

Ratio precio-beneficio (PE)

¿Está QSOA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de QSOA
Ingresos	US$0
Coste de los ingresos	US$67.00m
Beneficio bruto	-US$67.00m
Otros gastos	US$25.50m
Beneficios	-US$92.50m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.52
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado QSOA a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción QSOA

Análisis de riesgos

Competidores de Surface Oncology, Inc.

DB:VSC

€51.9m

XTRA:MDG1

€20.6m

XTRA:HPHA

€106.7m

XTRA:2INV

€63.2m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Surface Oncology, Inc. Files Form 15

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021)

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Recent updates

Surface Oncology, Inc. Files Form 15

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021)

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.44 loss in 3Q 2021)

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.43 loss in 2Q 2021)

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology, Inc. Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

Surface Oncology, Inc. Presents New SRF388 Clinical Data At 2022 American Society of Clinical Oncology Annual Meeting

First quarter 2022 earnings released: EPS: US$0.13 (vs US$0.37 loss in 1Q 2021)

Surface Oncology, Inc. to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

Surface Oncology, Inc. Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Surface Oncology Announces the Presentation of New Data from the Ongoing Phase 1 Studies of SRF388 and SRF617

Investor sentiment improved over the past week

First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.81 profit in 1Q 2020)

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Investor sentiment deteriorated over the past week

Surface Oncology Collaborates with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors

Revenue beats expectations

Full year 2020 earnings released: EPS US$1.67 (vs US$1.97 loss in FY 2019)

New 90-day low: €5.95

Surface Oncology, Inc. Announces Resignation of Daniel S. Lynch as Member and Chairman, Effective April 1, 2021

Surface Oncology, Inc. Announces Executive Changes, Effective April 1, 2021

New 90-day high: €9.20

Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program

New 90-day high: €8.75

Surface Oncology, Inc. Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer

Revenue in line with expectations

Surface Oncology to Present Srf388 and Srf114 Preclinical Data At the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference

Surface Oncology, Inc. Announces Preclinical Data on SRF388

New 90-day high: €6.05

New 90-day high - €5.95

Earnings released

Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell Microcap Value Index

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Surface Oncology, Inc.

0.0x

-0.7x

Beneficios e Ingresos